Stock listing
Caliway Biopharmaceuticals Co Ltd
Selected listing: 6919 · TWSE · TWD · TW
Caliway Biopharmaceuticals Co Ltd (TWSE:6919), Health Technology. Latest release Sep 23, 2026: Caliway Announces Positive Phase 2 Results of CBL-514…
- Ticker
- TWSE:6919
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- TWSE
- Currency
- TWD
About Caliway Biopharmaceuticals Co Ltd
Caliway Biopharmaceuticals Co Ltd, trading under the ticker 6919, is a public company listed on the Taiwan stock market. Caliway focuses on the development and commercialization of biopharmaceutical products.
Latest news from Caliway Biopharmaceuticals Co Ltd
Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum's Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction
September 22, 2026
Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment
August 25, 2026
Caliway Announces U.S. FDA IND Clearance for CBL-0302, Its Second Global Pivotal Phase 3 Study of CBL-514
May 22, 2026
Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global Pharmaceutical Companies for Its Systemic Metabolic Effects
May 19, 2026
Caliway's Fat Reduction Drug CBL-514 Phase 2 Clinical Results Accepted by ASJ. CBL-0204's Demonstrated Efficacy and Safety Gain Further Academic Recognition
April 13, 2026
Research Caliway Biopharmaceuticals Co Ltd
Caliway Biopharmaceuticals Co Ltd company profile
View the public company page for Caliway Biopharmaceuticals Co Ltd on 6ix.
Caliway Biopharmaceuticals Co Ltd news
Read company news and market updates connected to Caliway Biopharmaceuticals Co Ltd.
Caliway Biopharmaceuticals Co Ltd investor events
Find investor webinars, events, and replay context for Caliway Biopharmaceuticals Co Ltd.